B of A Securities Maintains Buy on Krystal Biotech, Raises Price Target to $396

Krystal Biotech, Inc.

Krystal Biotech, Inc.

KRYS

0.00

B of A Securities analyst Alec Stranahan maintains Krystal Biotech (NASDAQ: KRYS) with a Buy and raises the price target from $364 to $396.